Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

dc.contributor.authorGorin N.C.
dc.contributor.authorLabopin M.
dc.contributor.authorRocha V.
dc.contributor.authorArcese W.
dc.contributor.authorBeksac M.
dc.contributor.authorGluckman E.
dc.date.accessioned2024-07-12T21:45:15Z
dc.date.available2024-07-12T21:45:15Z
dc.date.issued2003en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractSeveral studies have compared bone marrow (BM) and peripheral blood (PB) as stem cell sources in patients receiving allografts, but the cell doses infused have not been considered, especially for BM. Using the ALWP/EBMT registry, we retrospectively studied 881 adult patients with acute myelocytic leukemia (AML), who received a non-T-depleted allogeneic BM (n = 515) or mobilized PB (n = 366) standard transplant, in first remission (CR1), from an HLA-identical sibling, over a 5-year period from January 1994. The BM cell dose ranged from 0.17 to 29 × 10 8 /kg with a median of 2.7 × 10 8 /kg. The PB cell dose ranged from 0.02 to 77 × 10 8 /kg with a median of 9.3 × 10 8 /kg. The median dose for patients receiving BM (2.7 × 10 8 /kg) gave the greatest discrimination. In multivariate analyses, high-dose BM compared to PB was associated with lower transplant-related mortality (RR = 0.61; 95% CI, 0.39-0.98; P = .04), better leukemia-free survival (RR = 0.65; 95% CI, 0.46-0.91; P = .013), and better overall survival (RR = 0.64; 95% CI, 0.44-0. 92; P = .016). The present study in patients with AML receiving allografts in first remission indicates a better outcome with BM as compared to PB, when the dose of BM infused is rich. © 2003 by The American Society of Hematology.en_US
dc.identifier.doi10.1182/blood-2003-03-0665
dc.identifier.endpage3051en_US
dc.identifier.issn0006-4971
dc.identifier.issue8en_US
dc.identifier.pmid12829583en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage3043en_US
dc.identifier.urihttps://dx.doi.org/10.1182/blood-2003-03-0665
dc.identifier.urihttps://hdl.handle.net/20.500.12415/7816
dc.identifier.volume102en_US
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAmerican Society of Hematologyen_US
dc.relation.ispartofBlooden_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY00432
dc.titleMarrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrowen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar